DIC (Disseminated Intravascular Coagulation) Scoring Calculator

About the DIC (Disseminated Intravascular Coagulation) Scoring Calculator

The DIC (Disseminated Intravascular Coagulation) Scoring Calculator uses the International Society on Thrombosis and Haemostasis (ISTH) scoring system to diagnose overt disseminated intravascular coagulation — a life-threatening condition involving widespread activation of the coagulation cascade leading to simultaneous thrombosis and hemorrhage.

DIC is not a standalone disease but a complication of underlying conditions including sepsis, major trauma, malignancy (especially acute promyelocytic leukemia), obstetric emergencies, and severe organ injury. The pathophysiology involves uncontrolled thrombin generation that consumes platelets and clotting factors (consumptive coagulopathy) while simultaneously forming microthrombi that cause organ damage.

The ISTH scoring system evaluates four laboratory parameters: platelet count, D-dimer/fibrin degradation products, prothrombin time (PT) prolongation, and fibrinogen level. A score of ≥5 is compatible with overt DIC; scores of 3–4 suggest non-overt (early) DIC requiring repeat testing. This calculator also classifies the DIC phenotype (hemorrhagic vs. thrombotic) to frame review context — a useful distinction because the broader bleeding-versus-thrombotic picture changes how teams interpret the score.

When This Page Helps

DIC is a medical emergency with mortality rates of 40–80% depending on the underlying cause. Early recognition using the ISTH score — combined with identification of the DIC phenotype — helps organize bedside review of a very high-risk coagulation picture. The scoring system is reproducible, objective, and endorsed by international guidelines for both diagnosis and monitoring treatment response.

How to Use the Inputs

1. Confirm that the patient has a known underlying condition associated with DIC (sepsis, trauma, malignancy, etc.).
2. Enter the platelet count category.
3. Enter the D-dimer/FDP elevation level.
4. Enter the PT prolongation in seconds above normal.
5. Enter the fibrinogen level.
6. Indicate whether there is clinical bleeding or organ failure/thrombosis.
7. Review the DIC score, interpretation, phenotype classification, and treatment guidance.

Example Calculation

Tips & Best Practices

• The ISTH score requires an underlying condition known to cause DIC — do not apply it without this prerequisite.
• DIC scoring should be repeated every 12–24 hours to monitor response to treatment and disease progression.
• Treat the underlying cause FIRST — DIC will not resolve until the trigger is controlled (e.g., antibiotics for sepsis, delivery for obstetric causes).
• Acute promyelocytic leukemia (APL) causes a uniquely severe DIC that requires emergent ATRA therapy in addition to standard DIC management.
• A rising score on serial measurements despite treatment suggests the underlying cause is not controlled.
• Fibrinogen <100 mg/dL is a critical threshold — replace with cryoprecipitate (each unit raises fibrinogen ~5–10 mg/dL).

Pathophysiology of DIC

DIC begins with massive tissue factor exposure (from damaged endothelium, activated monocytes, or tumor cells) that triggers widespread thrombin generation. This causes: (1) diffuse fibrin deposition in small vessels → microthrombi → organ ischemia and failure, (2) consumption of platelets and clotting factors → hemorrhage, (3) secondary fibrinolysis → elevated D-dimer/FDP, and (4) microangiopathic hemolytic anemia (schistocytes on smear). The net result is a paradoxical state of simultaneous thrombosis and bleeding.

Serial Monitoring with the ISTH Score

A single DIC score is a snapshot; serial scoring is essential for clinical management. An improving score (decreasing by 1–2 points over 24–48 hours) suggests treatment is working. A static or worsening score despite supportive care indicates the underlying cause is not controlled and requires escalation of therapy. Labs should be drawn every 8–12 hours in acute DIC.

Special Considerations in DIC Management

Acute promyelocytic leukemia (APL) is unique: ATRA (all-trans retinoic acid) must be started emergently upon suspicion, as it directly addresses the DIC by inducing differentiation of malignant promyelocytes. Obstetric DIC typically resolves with delivery of the placenta. Trauma-DIC management follows damage control resuscitation principles with massive transfusion protocols. COVID-19-associated coagulopathy shares some features with DIC but is typically more thrombotic, requiring different management.

Frequently Asked Questions

• What is DIC?

  Disseminated Intravascular Coagulation (DIC) is a complex, life-threatening condition where the coagulation system is abnormally activated throughout the body, leading to widespread microthrombi formation (causing organ damage) and simultaneous consumption of platelets and clotting factors (causing hemorrhage). It is always secondary to an underlying condition like sepsis, trauma, or malignancy.

• What is the difference between overt and non-overt DIC?

  Overt DIC (ISTH score ≥5) represents fully decompensated coagulopathy with clinical bleeding and/or thrombosis and clear laboratory abnormalities. Non-overt DIC (score 3–4) represents a compensated or early stage where the body is still partially maintaining hemostasis. Non-overt DIC requires close monitoring as it commonly progresses to overt DIC.

• How is DIC treated?

  The cornerstone of DIC treatment is addressing the underlying cause. Supportive care depends on the phenotype: hemorrhagic DIC → platelet transfusion (goal >50k), FFP (15–20 mL/kg), and cryoprecipitate (if fibrinogen <100). Thrombotic DIC → consider low-dose heparin. Universal measures include antithrombin replacement if AT <50% and avoiding intramuscular injections.

• What causes DIC?

  Common causes include: sepsis (most common, especially gram-negative), major trauma/burns, acute promyelocytic leukemia (APL), pancreatic/ovarian cancer, obstetric emergencies (placental abruption, amniotic fluid embolism, HELLP syndrome), transfusion reactions, snake envenomation, and vascular malformations.

• Can DIC be both thrombotic and hemorrhagic?

  Yes — many patients have a mixed phenotype with both microvascular thrombosis (causing organ failure) and hemorrhage (from consumption of clotting factors). The relative predominance depends on the underlying cause, disease stage, and the rate of coagulation activation. Treatment must balance replacement therapy against anticoagulation based on the predominant phenotype.

• What is the mortality rate of DIC?

  DIC mortality varies widely by underlying cause: sepsis-associated DIC has 40–80% mortality, trauma-associated DIC 20–50%, and obstetric DIC 5–20% (generally better prognosis because delivery addresses the cause). Higher ISTH DIC scores correlate with higher mortality. Early recognition and aggressive treatment of the underlying cause are the most important prognostic factors.